iZafe Group

iZafe Group Gross Margin

The Gross Margin of iZafe Group (IZAFE B.ST) as of Nov 19, 2026 is -259.71 %. In the previous year, Gross Margin was -20.54 % — a change of 1,164.20% (lower).

Gross Margin

-259.71 %

YoY

1,164.20%

Last updated:

Gross Margin of iZafe Group is 2025 -259.71 % . Gross Margin of iZafe Group was 2024 -20.54 % . It decreases by 1,164.20% lower compared to the previous year.

For iZafe Group, the gross margin of -259.7% is down versus -257.5% a few years ago.

The iZafe Group Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
-141.75 SEK
Jan 1, 2019
-153.73 SEK
Jan 1, 2020
85.86 SEK
Jan 1, 2021
-257.47 SEK
Jan 1, 2022
16.87 SEK
Jan 1, 2023
16.08 SEK
Jan 1, 2024
-20.54 SEK
Jan 1, 2025
-259.71 SEK
The iZafe Group Gross Margin history
YEARGross MarginYoY
-259.71 %+1,164.20%
-20.54 %-227.75%
16.08 %-4.69%
16.87 %-106.55%
-257.47 %-399.87%
85.86 %-155.85%
-153.73 %+8.45%
-141.75 %-95.36%
-3,056.77 %+1,328.00%
-214.06 %+526.94%
-34.14 %-3,514.36%
1.00 %0.00%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iZafe Group Stock analysis

What does iZafe Group do? iZafe Group AB develops medical and digital security solutions, including Dosell, a patented drug dispenser for home medication with remote monitoring, and MediKoll, an app providing medication side effect and allergy information. The company serves pharmaceutical companies, hospitals, care homes, and pharmacies in the global market. Its products target patients and healthcare providers seeking secure, remote medication management and personalized health information. Dosell is under development as a home medication solution, while MediKoll offers real-time data on medication reactions. The firm's revenue comes from selling these digital tools to healthcare institutions and pharmaceutical partners, focusing on improving patient safety and reducing medication errors through technology. iZafe Group AB's business model relies on the global healthcare sector's demand for innovative digital tools. The company's offerings are tailored for pharmaceutical firms, hospitals, care homes, and pharmacies, leveraging remote monitoring capabilities to address medication management challenges in home and clinical settings. iZafe Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iZafe Group stock

Gross Margin of iZafe Group is -259.71 % in 2025.

Gross Margin of iZafe Group changed from -20.54 % to -259.71 %, representing a 1,164.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin iZafe Group since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's iZafe Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — iZafe Group

All Key Metrics — iZafe Group